EGFL7 Active Protein | EGFL active protein

Human EGFL7 Recombinant

Cat. Num. AAA76105

• Purity: >90%, as determined by SDS-PAGE
• Synonyms: EGFL7; N/A; Human EGFL7 Recombinant; ve-statin; EGFL active protein

• Host: Insect Cells (Host protein expression may be lot-specific and can be subject to change during production, including bulk orders)
• Purity/Purification: >90%, as determined by SDS-PAGE
• Form/Format: Recombinant Human EGFL7 is lyophilized 0.2 um filtered 100mM glycine, 10mM NaCl, 10% Glycerol solution pH 7.0 and 5% trehalose.
• Sequence Length: 273

• Domain: EGF,EMI
• Host Note: DNA sequence encoding mature chain of Human EGFL7 (VE-Statin) to a C-terminal polyHis tag was expressed in Insect cells.
• Biological Activity: The activity was determined by the ability to bind human NOTCH1 in functional ELISA.
• Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1mg/ml. It is recommended to add 0.1% BSA for long term storage of reconstituted product.
• Endotoxin: Endotoxin content was assayed using a LAL gel clot method.; Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug).
• Molecular Weight Note: Recombinant Human EGFL7 is a monomer consisting of 268 amino acid residue, and migrates as an approximately 31 kDa protein under reducing conditions in SDS-PAGE.
• Preparation and Storage: Lyophilized EGFL7, as supplied, should be stored at -20 degree C to -70 degree C.; Upon reconstitution, working aliquots may be stored at 2 - 8 degree C for one month, or six months at -20 degree C without detecable loss of activity. It is recommended to add 0.1% BSA for long term storage. Avoid freeze/thaw cycles.

Related Product Information for EGFL active protein

EGFL7 is an 30 kDa secreted protein that contain an Emilin-like (EMI) domain, and 2 epidermal growth factor (EGF) domains, one of which binds calcium. Based on these domains, it has been hypothesized that EGFL7 may self-assemble like extracellular matrix (ECM) proteins and, thus, could incorporate into ECM. EGFL7 has been reported to stimulate cell adhesion as well as motility in a manner similar to ECM proteins. EGFL7 has been shown to be primarily expressed by developing ECs but also by primordial germ cells and some central nervous system neurons. Interestingly, EGFL7 expression markedly decreases in ECs in postnatal life, but can be strongly up-regulated after various tissue injuries that lead to increased angiogenic responses.

Product Categories/Family for EGFL active protein

Cytokines

References

• EGFL7: a unique angiogenic signaling factor in vascular development and disease .Blood, Dec 2011; 10.1182/blood-2011-10-322446.
• EGFL7 promotes tumor escape from immunity by repressing endothelial cell activation .Cancer Res., Dec 2011; 71: 7176 - 7186.
• gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis related genes acvrl1 and EGFL7 in early-onset disease .Mol. Hum. Reprod., Oct 2011; 10.1093/molehr/gar067.
• population pharmacokinetic (pk) analysis supports fixed dosing for the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) administered intravenously in patients with advanced solid tumors. .ASCO Meeting Abstracts, May 2011; 29: 2586.
• a phase ib dose-escalation study of the safety, pharmacokinetics (pk), pharmacodynamics (pd), and antitumor activity of the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. .ASCO Meeting Abstracts, May 2011; 29: 2514.